Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Joint Authors
Mitchell, Ian
Harimoto, Tetsuhiro
Lanctôt, Krista L.
Paes, Bosco
Li, Abby
Source
Clinical and Developmental Immunology
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-06-19
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality.
Palivizumab has been available for prophylaxis for the past 15 years.
Prospective data on patients who received palivizumab from 2005 to 2012 has been assembled in the Canadian registry (CARESS) to document utilization, compliance, and health outcomes in both hospital and community settings.
Long-term data is necessary to evaluate the impact of palivizumab on the incidence of RSV infections, minimize healthcare resources, and identify which infant subpopulations are receiving prophylaxis.
A database search was also conducted for similar information from published registries, and hospitalization rates were compared to results from randomized clinical trials (RCTs).Overall hospitalization rates (percent; range) for respiratory-related illnesses and RSV-specific infection in infants who meet standard indications for prophylaxis were 6.6 (3.3–7.7) and 1.55 (0.3–2.06), respectively, in CARESS, which closely aligns with registry data from 4 other countries, despite the former comprising the largest cohort of complex patients internationally.
Overall RSV-related hospitalization rates were lower across registries compared to equivalent patients in RCTs.
Registry data provides valuable information regarding real-world experience with palivizumab, while facilitating the genesis of new research themes.
American Psychological Association (APA)
Paes, Bosco& Mitchell, Ian& Li, Abby& Harimoto, Tetsuhiro& Lanctôt, Krista L.. 2013. Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries. Clinical and Developmental Immunology،Vol. 2013, no. 2013, pp.1-15.
https://search.emarefa.net/detail/BIM-507919
Modern Language Association (MLA)
Paes, Bosco…[et al.]. Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries. Clinical and Developmental Immunology No. 2013 (2013), pp.1-15.
https://search.emarefa.net/detail/BIM-507919
American Medical Association (AMA)
Paes, Bosco& Mitchell, Ian& Li, Abby& Harimoto, Tetsuhiro& Lanctôt, Krista L.. Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries. Clinical and Developmental Immunology. 2013. Vol. 2013, no. 2013, pp.1-15.
https://search.emarefa.net/detail/BIM-507919
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-507919